Loading...
Market
Will FDA approve psilocybin therapy for depression in healthcare workers by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Psilocybin Therapy Cuts Depression by Over 70% in COVID Healthcare Workers
Dec 5, 2024, 04:07 PM
A study published by the American Medical Association has found that psilocybin therapy, derived from magic mushrooms, led to a significant and sustained reduction in symptoms of depression among frontline healthcare workers, including doctors and nurses, who served during the COVID-19 pandemic. The therapy reduced depression scores by over 70%, compared to a 30% reduction observed with a placebo. Participants experienced an average drop in depression scores, underscoring the potential of psilocybin as a therapeutic option for mental health challenges faced by healthcare professionals.
View original story
Similar markets
Increased funding • 25%
Decreased funding • 25%
No funding • 25%
Same level of funding • 25%
Effective only for PTSD • 25%
Not effective for either condition • 25%
Effective for both PTSD and alcohol use disorder • 25%
Effective only for alcohol use disorder • 25%
No • 50%
Yes • 50%
6-10 states • 25%
2 or fewer states • 25%
3-5 states • 25%
More than 10 states • 25%
Conditional Approval • 25%
Withdrawn by Axsome • 25%
Rejected • 25%
Approved • 25%
Ayahuasca • 25%
Other • 25%
LSD • 25%
Psilocybin • 25%